Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Andrx loratadine

This article was originally published in The Tan Sheet

Executive Summary

Generics maker receives tentative FDA approval of ANDA (75-990) for orally disintegrating loratadine tablets (Schering's Claritin Reditabs) Nov. 15. Andrx previously was granted tentative approval for 24-hour loratadine/ pseudoephedrine combination (Claritin-D 24-Hour), for which it holds "first-to-file" status. Wyeth has said it holds FTF ANDA status for orally disintegrating loratadine (1"The Tan Sheet" Nov. 4, 2002, In Brief). FDA's target action date on Schering's switch NDAs for Claritin is Nov. 28; loratadine compound patent exclusivity expires Dec. 19...

You may also be interested in...

Wyeth Loratadine Exclusivity Should Reflect Alavert Approval Date – Andrx

Marketing exclusivity for Wyeth Consumer Healthcare's generic loratadine tablets should begin on "the date on which Wyeth began marketing generic loratadine in its product Alavert," rival marketer Andrx asserts in a Feb. 27 citizen petition

Wyeth OTC loratadine

Company says it holds "first to file" ANDA status for orally disintegrating loratadine (Schering's Claritin Reditabs). Wyeth also has a pending 505(b)(2) application for OTC sale of the product. Firm recently told analysts Alavert launch would not be sidelined for six months by exclusivity issues (1"The Tan Sheet" Oct. 28, 2002, p. 4)...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts